Acquisition to boost Genzyme's surgical business
This article was originally published in Clinica
Genzyme's General Division plans to acquire Deknatel Snowden Pencer (DSP), a privately-held surgical products company, for $250 million in cash. The proposed purchase, which is expected to close by the end of June, should add $50 million to Genzyme's revenue this year. Genzyme's 1995 turnover was $379 million.